These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18483391)

  • 1. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
    Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
    Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
    Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
    Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
    Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
    Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
    Li Q; Zhu Y; He J; Wang M; Zhu M; Shi T; Qiu L; Ye D; Wei Q
    Mol Biol Rep; 2013 May; 40(5):3597-608. PubMed ID: 23277398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
    Tong M; Jin YY; Li G; Liu SM; Ji CD
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
    Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
    Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H; Stampfer MJ; Hollis JB; Mucci LA; Gaziano JM; Hunter D; Giovannucci EL; Ma J
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
    Febbo PG; Kantoff PW; Platz EA; Casey D; Batter S; Giovannucci E; Hennekens CH; Stampfer MJ
    Cancer Res; 1999 Dec; 59(23):5878-81. PubMed ID: 10606227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
    Li J; Coates RJ; Gwinn M; Khoury MJ
    Am J Epidemiol; 2010 Jan; 171(1):1-13. PubMed ID: 19914946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
    Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
    Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis.
    Wang K; Wu G; Li J; Song W
    BMC Cancer; 2016 Aug; 16(1):674. PubMed ID: 27553621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.